Dendrite Awarded Field Support Services Contract by Leading European Pharmaceutical Company

  
    
  
  
    
      Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of 
      pharmaceutical industry solutions, today announced that the company has 
      signed a three-year field support services agreement with a prominent 
      European pharmaceutical company. Under the terms of the agreement, 
      Dendrite will provide premium help desk and hardware services for the 
      company’s French operation, which uses a 
      third-party based CRM solution. The operation will be staffed and 
      managed by an onsite Dendrite team based at the pharmaceutical company’s 
      local offices.
    
    
      “We’re confident 
      that with our history of successfully supporting premium field 
      organizations — both on our sales force 
      effectiveness solutions as well as third-party systems, this customer 
      will have the tools needed to achieve higher productivity returns,” 
      said Mario Mauri, president of Dendrite Europe.
    
    
      Dendrite’s premium field support services are 
      designed to enable higher field representative productivity for life 
      science companies around the world. These services are provided in the 
      local language, within local time zones and are available at the 
      customer location or as a syndicated service.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, 
      marketing, clinical and compliance solutions for the global, 
      pharmaceutical industry. The Company’s clients 
      are located in more than 50 countries and include the world's top 20 
      pharmaceutical companies. For more information, please visit www.dendrite.com.
    
    
      Note: Dendrite is a registered trademark of Dendrite International, Inc.
    
    
      This document may contain forward-looking statements that may be 
      identified by such forward-looking terminology as "expect," "believe," 
      "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," 
      and similar statements or variations. Such forward-looking statements 
      are based on our current expectations, estimates, assumptions and 
      projections and involve significant risks and uncertainties, including 
      risks which may result from our dependence on the pharmaceutical 
      industry; fluctuations in quarterly revenues due to lengthy sales and 
      implementation cycles for certain of our solutions; our fixed expenses 
      in relation to fluctuating revenues and variations in customers' budget 
      cycles; dependence on certain major customers; changes in demand for our 
      products and services attributable to any weakness experienced in the 
      economy or mergers, acquisitions and consolidations in the 
      pharmaceutical industry; successful and timely development and 
      introduction of new products and versions; rapid technological changes; 
      increased competition; international operations; integrating the 
      entities we acquire; our ability to effectively manage our growth; the 
      protection of our proprietary technology; our ability to compete in the 
      Internet-related products and services market; the continued demand for 
      Internet-related products and services; the ability of our third party 
      vendors to respond to technological change; our ability to maintain our 
      relationships with third-party vendors; less favorable than anticipated 
      results from strategic relationships; dependence of data solutions on 
      strategic relationships; events which may affect the U.S. and world 
      economies; and catastrophic events which could negatively affect our 
      information technology infrastructure. Other important factors that 
      should be reviewed and carefully considered are included in the 
      company's 10-K, 10-Qs, and other reports filed with the SEC. Actual 
      results may differ materially. The company assumes no obligation for 
      updating any such forward-looking statements to reflect actual results, 
      changes in assumptions or other changes affecting such forward-looking 
      statements.
    
  
Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of
pharmaceutical industry solutions, today announced that the company
has signed a three-year field support services agreement with a
prominent European pharmaceutical company. Under the terms of the
agreement, Dendrite will provide premium help desk and hardware
services for the company's French operation, which uses a third-party
based CRM solution. The operation will be staffed and managed by an
onsite Dendrite team based at the pharmaceutical company's local
offices.

   "We're confident that with our history of successfully supporting
premium field organizations -- both on our sales force effectiveness
solutions as well as third-party systems, this customer will have the
tools needed to achieve higher productivity returns," said Mario
Mauri, president of Dendrite Europe.

   Dendrite's premium field support services are designed to enable
higher field representative productivity for life science companies
around the world. These services are provided in the local language,
within local time zones and are available at the customer location or
as a syndicated service.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global,
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.